Evidence map›Paper›PMID 40964971›Full record

ArticleBiomarkers in medicine2025

Expression and significance of

Tingting Zeng, Lulu Zeng, Qianbin Dai, Yao Zhou, Qing Luo, Lu Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarkers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tingting ZengDepartment of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Lulu ZengDepartment of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Qianbin DaiDepartment of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Yao ZhouDepartment of Rheumatology, the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Qing LuoDepartment of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Lu ZhangDepartment of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimA retrospective study was designed to compare the expression levels of TNF superfamily member 12 (TNFSF12), which encodes the protein TNF-like weak inducer of apoptosis (TWEAK), and CD163 in peripheral blood monocytes between rheumatoid arthritis (RA) patients and controls, and to correlate their expression with clinical parameters to investigate their potential association with RA. MATERIALS &

methodsRT-qPCR method was used to determine gene expression of TNFSF12 and CD163 in patients with RA, ankylosing spondylitis (AS) and healthy controls (HC). ROC curve, Pearson correlation analysis, and western blot were used to access the diagnostic performance of TNFSF12/TWEAK and CD163, analyze their correlation with other clinical parameters in RA, and evaluate the protein expression of TWEAK and CD163 in RA.

resultsTNFSF12 and CD163 in RA patients were higher expressed compared with AS and HC; they were helpful to identify RA patients from controls, with area under ROC curve (AUC) being 0.813 and 0.826, respectively, and correlated with ESR and CRP. TWEAK and CD163 in monocytes from RA were significantly upregulated compared with controls.

conclusionTNFSF12 and CD163 gene higher expressed in RA patients and related with therapeutic response and inflammation status, can be used as reference index for RA diagnosis and disease monitoring.

Indexed as

Antigens, CDAntigens, Differentiation, MyelomonocyticArthritis, RheumatoidCytokine TWEAKMonocytesReceptors, Cell SurfaceAdultBiomarkersCase-Control StudiesCD163 AntigenFemaleHumansMaleMiddle AgedRetrospective StudiesROC CurveAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkersCD163 AntigenCytokine TWEAKReceptors, Cell SurfaceTNFSF12 protein, humanbiomarkerCD163Rheumatoid arthritisTNFSF12TWEAK

Identifiers

PMID40964971
PMCPMC12477863

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.